- Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysisWang, Ting; Cai, Liyu; Guo, Zefeng; You, Peimeng; Liu, Shengbo; Qiu, Hongrui; Li, Hao; Wu, Shaowei; Zhou, HaiyuAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- ASO Visual Abstract: Early and Persistent Dysphagia Relief Predicts Tumor Response in Esophageal Squamous Cell Carcinoma Patients Treated with ImmunochemotherapyHuang, Shujie; Tang, Yong; Wu, Hansheng; Shi, Qiuling; Tang, Jiming; Ben, Xiaosong; Zhang, Dongkun; Xie, Liang; Zhou, Haiyu; Chen, Gang; Wang, Sichao; Gao, Zhen; Xie, Zefeng; Chen, Rixin*; Qiao, Guibin*Annals of Surgical Oncology, 2023.被引 1
- Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinomaLiu, Jianhua; Zhang, Jia-Tao; Zhu, Changbin; Li, Weiwei; Li, Qian; Huang, Zhan; Qiao, Guibin; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Induction immunochemotherapy conversion rate and survival outcomes versus chemotherapy in initially unresectable esophageal squamous cell carcinoma
18阅读
